Vistagen Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Vistagen Therapeutics

05/08/2025 21:58

Vistagen Therapeutics Inc VTGN.OQ VTGN.O is expected to  show a rise in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The South San Francisco California-based  company is expected to report a 673.8% increase in revenue to $650 thousand from $84 thousand a year ago, according to the estimate from one analyst, based on LSEG data.

​LSEG's mean analyst estimate for Vistagen Therapeutics Inc is for a loss of 47 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $12.00, about 75.8% above its last closing price of $2.91

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.52
-0.50
-0.43
Beat
13
Dec. 31 2025
-0.51
-0.51
-0.46
Beat
9.8
Sep. 30 2024
-0.39
-0.39
-0.42
Missed
-7.7​
Jun. 30 2024
-0.41
-0.40
-0.35
Beat
13.6
​​Mar. 31 2024
-0.33
-0.36
-0.25
Beat
31
Dec. 31 2023
-0.28
-0.30
-0.22
Beat
27.3​
Sep. 30 2023
-0.68
-0.68
-0.66
Beat
2.9

This summary was machine generated August 5 at 20:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)